Tobacco treatment and prevention: What works and why

Respiratory Care

Volumn 54, Issue 8, 2009, Pages 1082-1090

  Goodfellow, Lynda T ^a   Waugh, Jonathan B ^b  

^a GEORGIA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Chronic lung disease; Chronic obstructive pulmonary disease; COPD; Nicotine dependence; Nicotine replacement therapy; Respiratory therapist; Smoking cessation; Tobacco abuse; Tobacco control; Tobacco treatment

Indexed keywords

ALCOHOL; AMFEBUTAMONE; BENZODIAZEPINE DERIVATIVE; CAFFEINE; CLONIDINE; ERGOT ALKALOID; INSULIN; NICOTINE GUM; NICOTINE PATCH; NICOTINE VACCINE; NICOTINIC AGENT; NORTRIPTYLINE; PLACEBO; VARENICLINE;

AGITATION; APPLICATION SITE IRRITATION; APPLICATION SITE REACTION; BEHAVIOR CHANGE; BLURRED VISION; CARBONATED BEVERAGE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COFFEE; CONFERENCE PAPER; CONSTIPATION; COUNSELING; DEPRESSION; DIZZINESS; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; FATIGUE; FLATULENCE; FOOD; GOVERNMENT REGULATION; HEALTH CARE DELIVERY; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; INSOMNIA; IRRITABILITY; LIVER TOXICITY; LOW DRUG DOSE; MAJOR DEPRESSION; MONOTHERAPY; MOOD CHANGE; MORNING DOSAGE; NAUSEA; NEPHROTOXICITY; NICOTINE REPLACEMENT THERAPY; PASSIVE SMOKING; PATIENT EDUCATION; PREVENTION AND CONTROL; RESPIRATORY THERAPIST; SEXUAL DYSFUNCTION; SIDE EFFECT; SMOKING CESSATION; SMOKING CESSATION PROGRAM; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; TINNITUS; TOBACCO DEPENDENCE; TREMOR; VIVID DREAM; WEAKNESS; WEIGHT GAIN; WITHDRAWAL REFLEX;

CENTRAL NERVOUS SYSTEM STIMULANTS; HEALTH PROMOTION; HUMANS; NICOTINE; NICOTINIC AGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY THERAPY; SMOKING CESSATION; SOCIAL CONTROL, FORMAL;

EID: 68549139914     PISSN: 00201324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (44)

1. Musk AW, deKlerk NH. History of tobacco and health. Respirology 2003;8(3):286-290.
2. Henningfield JE. Nicotine: an old fashioned addiction. Cohen M, editor. New York: Chelsea House Publications; 1985:96-98.
3. Szollosi-Janze M. Science in the Third Reich. Oxford: Berg; 2001.
4. Proctor RN, The anti-tobacco campaign of the Nazis: a little known aspect of public health in Germany 1933-1945. BMJ 1996;313(7070): 1450-1453.
5. Lickint F. Tabakgenuss und gesundheit. Hannover: Bruno Wilkens Verlag; 1936:260-265. Text in German.
6. Basham P, Luik J. The hidden dangers of the smoking ban: could the ban on lighting-up in public in England and Wales lead to more dangerously polluted air in the home-and even to more house fires? Spiked Online;2007. http://www.spiked-online.com/index.php?/site/ article/3593. Accessed June 11, 2009.
7. Centers for Disease Control and Prevention. Indoor air quality in hospitality venues before and after implementation of a clean indoor air law: western New York, 2003. Morb Mortal Wkly Rep 2004; 53(44):1038-1041.
8. Alright S. The impact of banning smoking in workplaces: what are the early effects? App Health Econ Health Policy 2008;6(2-3):81-92.
9. Farrelly MC, Evans WN, Sfekas AE. The impact of workplace smoking bans: results from a national survey. Tob Control 1999;8(3):272-277.
10. Goodman P, Agnew M, McCaffrey M, Paul G, Clancy L. Effects of the Irish smoking ban on respiratory health of bar workers and air quality in Dublin pubs. Am J Respir Crit Care Med 2007;175(8): 840-845. (Pubitemid 46631796)
11. Godfrey F. Hold the front page: smoking bans good for (most) workers' health. Am J Respir Crit Care Med 2007;175(8):751-753. (Pubitemid 46631783)
12. Centers for Disease Control and Prevention. Decline in smoking prevalence: New York City, 2002-2006. Morb Mortal Wkly Rep 2007;56(24):604-608.
13. Centers for Disease Control and Prevention. State-specific prevalence and trends in adult cigarette smoking: United States, 1998- 2007. Morb Mortal Wkly Rep 2009;58(09):221-226.
14. World Lung Foundation, American Cancer Society. The Tobacco Atlas 2009. http://www.tobaccoatlas.org. Accessed June 11, 2009.
15. Alpert HR, Carpenter CM, Travers MJ, Connolly GN. Environmental and economic evaluation of the Massachusetts smoke-free workplace law. J Comm Health 2007;32(4):269-281.
16. Greeman M, McClellan TA. Negative effects of a smoking ban on an inpatient psychiatry service. Hosp Community Psychiatry 1991;42(4): 408-412.
17. Ziedonis D, Hitsman B, Beckham JC, Zvolensky M, Adler LE, Audrian- McGovern J, et al. Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nicotine Tob Res 2008;10(12):1691-1715.
18. Oliver D, Lubman DI, Fraser R. Tobacco smoking within psychiatric inpatient settings: biopsychosocial perspective. Aust N Z Psychiatry 2007;41(7):572-580. (Pubitemid 46930094)
19. Levy DT, Chaloupka F, Mitchell J. The effects of tobacco control policies on smoking rates: a tobacco control scorecard. J Pub Health Manag Pract 2004;10(4):338-353.
20. Fiore MC, Jaen CR, Baker TB, Bailey WC, Benowitz N, Curry SJ, et al. Treating tobacco use and dependence: 2008 update. US Dept of Health and Human Services, Public Health Service; May 2008.
21. George TP. Medication treatments for nicotine dependence. Boca Raton: CRC/Taylor & Francis; 2007.
22. Pidoplichko VI, DeBiasi M, Williams JT, Dani JA. Nicotine activates and desensitizes midbrain dopamine neurons. Nature 1997; 390(6658):401-404. (Pubitemid 28027320)
23. Imperato A, Mulas A, Di Chiara G. Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur J Pharmacol 1986;132(2-3):337-338. (Pubitemid 17003483)
24. Stead L, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008;(1):CD000146. (Pubitemid 351807378)
25. Epifano L, Di Vincenzo A, Fanelli C, Porcellati F, Perriello G, De Feo P, et al. Effect of cigarette smoking and of a transdermal nicotine delivery system on glucoregulation in type 2 diabetes mellitus. Eur J Clin Pharmacol 1992;43(3):257-263.
26. Eliasson B. Cigarette smoking and diabetes. Prog Cardiovasc Dis 2003;45(5):405-413.
27. Fredrickson PA, Hurt RD, Lee GM, Wingender L, Croghan IT, Lauger G, et al. High-dose transdermal nicotine therapy for heavy smokers: safety, tolerability and measurement of nicotine and cotinine levels. Psychopharmacology (Berl) 1995;122(3):215-222.
28. Slemmer JE, Martin RM, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000;295(1):321-327.
29. Fryer JD, Lukas RJ. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 1999;288(6):88-92.
30. Love BL, Merz T. Varenicline (Chantix) for smoking cessation. Am Fam Physician 2007;76(2):19-20.
31. Oncken CA, Gonzales D, Nides M, Rennard S, Watsky EJ, Coe JW. Varenicline: an α4β2 nicotinic acetylcholine receptor partial agonist as an aid to smoking cessation. In: George TP, editor. Medication treatments for nicotine dependence. Boca Raton: CRC/Taylor&Francis; 2007;213-221.
32. Hays JT, Ebbert JO. Varenicline for tobacco dependence. N Engl J Med 2008;359(19):2018-2024.
33. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296(1):47-55.
34. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296(1):56-63.
35. Update panel, liaisons, and staff. A clinical practice guideline for treating tobacco use and dependence: 2008 update. Am J Prev Med 2008;35(2):158-176.
36. Fiore MC, Jaen CR, Baker TB, Bailey WC, Benowitz N, Curry SJ, et al; 2008 PHS Panel, liaisons, and staff. Treating tobacco use and dependence: 2008 update. US Public Health Service clinical practice guideline: executive summary. Respir Care 2008;53(9):1217-1222.
37. Volpp KG, Troxel AB, Pauly MV, Glick HA, Puig A, Asch DA, et al. A randomized, controlled trial of financial incentives for smoking cessation. N Engl J Med 2008;360(7):699-709.
38. Ling PM, Glantz SA. Tobacco industry research on smoking cessation: recapturing young adults and other recent quitters. J Gen Intern Med 2004;19(5 Pt 1):419-426.
39. Waugh JB, Lorish CD. New guideline on treating tobacco use and dependence: 2008 update is an opportunity to advance. Respir Care 2008;53(9):1166-1167.
40. Carpenter MJ, Hughes JR, Solomon LJ, Callas PW. Both smoking reduction with nicotine replacement therapy and motivational advice increase future cessation among smokers unmotivated to quit. J Consult Clin Psychol 2004;72(3):371-381.
41. Carpenter MJ, Hughes JR, Keely J. Effect of smoking reduction on later cessation: a pilot experimental study. Nicotine Tob Res 2003; 5(2):155-162. (Pubitemid 36546997)
42. Mularski RA, Asch SM, Shrank WH, Kerr EA, Setodji CM, Adams JL, et al. The quality of obstructive lung disease care for adults in the United States as measured by adherence to recommended process. Chest 2006;130(6):1844-1850.
43. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2008. http://www.goldcopd. com/. Accessed June 11, 2009.
44. Hejblum G, Atsou K, Dautzenberg B, Chouaid C. Cost-benefit analysis of a simulated institution-based preoperative smoking cessation intervention in patients undergoing total hip and knee arthroplasties in France. Chest 2009;135(2):477-483.